USD 1.71
(-1.72%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 42.51 Million USD | 51.58% |
2022 | 28.04 Million USD | 27.48% |
2021 | 22 Million USD | -57.71% |
2020 | 52.02 Million USD | 18.78% |
2019 | 43.79 Million USD | 75.63% |
2018 | 24.93 Million USD | 521.74% |
2017 | 4.01 Million USD | 400.75% |
2016 | 801 Thousand USD | -77.96% |
2015 | 3.63 Million USD | -40.49% |
2014 | 6.1 Million USD | 0.36% |
2013 | 6.08 Million USD | -76.85% |
2012 | 26.28 Million USD | 1721.21% |
2011 | 1.44 Million USD | 161.59% |
2010 | -2.34 Million USD | 26.48% |
2009 | -3.18 Million USD | 0.0% |
2008 | - USD | 0.0% |
2007 | - USD | -100.0% |
2006 | 115 Thousand USD | 0.0% |
2005 | - USD | 0.0% |
2004 | - USD | 0.0% |
2003 | - USD | 0.0% |
2002 | - USD | 0.0% |
2001 | - USD | -100.0% |
2000 | 1.00 USD | -100.0% |
1999 | 871.15 Thousand USD | -49.65% |
1998 | 1.73 Million USD | 0.0% |
1997 | - USD | 0.0% |
1996 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 1.14 Million USD | -29.69% |
2024 Q2 | 4.01 Million USD | 250.61% |
2023 Q1 | 6.5 Million USD | 4.55% |
2023 FY | 42.51 Million USD | 51.58% |
2023 Q3 | 5.45 Million USD | -81.15% |
2023 Q2 | 28.92 Million USD | 344.83% |
2023 Q4 | 1.63 Million USD | -70.1% |
2022 Q1 | 10.05 Million USD | 86.1% |
2022 Q2 | 4.66 Million USD | -53.58% |
2022 Q3 | 7.1 Million USD | 52.36% |
2022 FY | 28.04 Million USD | 27.48% |
2022 Q4 | 6.22 Million USD | -12.51% |
2021 Q2 | 1.69 Million USD | -74.16% |
2021 Q1 | 6.55 Million USD | -60.85% |
2021 Q3 | 8.35 Million USD | 392.98% |
2021 FY | 22 Million USD | -57.71% |
2021 Q4 | 5.4 Million USD | -35.33% |
2020 Q4 | 16.74 Million USD | 111.35% |
2020 Q1 | 18.22 Million USD | 23.03% |
2020 Q2 | 9.14 Million USD | -49.84% |
2020 Q3 | 7.92 Million USD | -13.33% |
2020 FY | 52.02 Million USD | 18.78% |
2019 Q3 | 11.04 Million USD | 15.61% |
2019 FY | 43.79 Million USD | 75.63% |
2019 Q1 | 8.39 Million USD | -66.07% |
2019 Q2 | 9.55 Million USD | 13.8% |
2019 Q4 | 14.8 Million USD | 34.1% |
2018 Q4 | 24.74 Million USD | 2072.89% |
2018 Q3 | -1.25 Million USD | -608.47% |
2018 Q1 | 1.62 Million USD | 78.03% |
2018 FY | 24.93 Million USD | 521.74% |
2018 Q2 | -177 Thousand USD | -110.87% |
2017 FY | 4.01 Million USD | 400.75% |
2017 Q2 | 835 Thousand USD | 4.24% |
2017 Q4 | 915 Thousand USD | -37.33% |
2017 Q3 | 1.46 Million USD | 74.85% |
2017 Q1 | 801 Thousand USD | 520.93% |
2016 Q1 | 156 Thousand USD | 103.04% |
2016 Q3 | 422 Thousand USD | 348.94% |
2016 Q2 | 94 Thousand USD | -39.74% |
2016 FY | 801 Thousand USD | -77.96% |
2016 Q4 | 129 Thousand USD | -69.43% |
2015 Q2 | 2.57 Million USD | -4.45% |
2015 FY | 3.63 Million USD | -40.49% |
2015 Q4 | -5.14 Million USD | -246.86% |
2015 Q3 | 3.5 Million USD | 35.82% |
2015 Q1 | 2.69 Million USD | 1497.41% |
2014 FY | 6.1 Million USD | 0.36% |
2014 Q4 | -193 Thousand USD | -110.11% |
2014 Q1 | 3.31 Million USD | 869.77% |
2014 Q3 | 1.9 Million USD | 76.6% |
2014 Q2 | 1.08 Million USD | -67.34% |
2013 Q1 | 2.99 Million USD | 365.22% |
2013 Q3 | 1.77 Million USD | 1.49% |
2013 FY | 6.08 Million USD | -76.85% |
2013 Q4 | -430 Thousand USD | -124.27% |
2013 Q2 | 1.74 Million USD | -41.74% |
2012 FY | 26.28 Million USD | 1721.21% |
2012 Q4 | -1.13 Million USD | -137.38% |
2012 Q3 | 3.02 Million USD | -86.76% |
2012 Q1 | 2.4 Million USD | 719.05% |
2012 Q2 | 22.83 Million USD | 848.26% |
2011 Q3 | 677 Thousand USD | 7.12% |
2011 Q2 | 632 Thousand USD | -87.9% |
2011 Q1 | 5.22 Million USD | 188.18% |
2011 Q4 | 294 Thousand USD | -56.57% |
2011 FY | 1.44 Million USD | 161.59% |
2010 Q2 | 1.14 Million USD | 0.0% |
2010 Q3 | 2.11 Million USD | 85.71% |
2010 FY | -2.34 Million USD | 26.48% |
2010 Q4 | -5.92 Million USD | -379.47% |
2010 Q1 | 1.14 Million USD | 135.8% |
2009 Q4 | -3.18 Million USD | 0.0% |
2009 Q3 | - USD | 0.0% |
2009 Q2 | - USD | 0.0% |
2009 FY | -3.18 Million USD | 0.0% |
2009 Q1 | - USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2008 FY | - USD | 0.0% |
2008 Q4 | - USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2007 Q2 | - USD | 0.0% |
2007 FY | - USD | -100.0% |
2007 Q4 | - USD | 0.0% |
2007 Q3 | - USD | 0.0% |
2007 Q1 | - USD | -100.0% |
2006 Q2 | - USD | 0.0% |
2006 Q1 | - USD | 0.0% |
2006 FY | 115 Thousand USD | 0.0% |
2006 Q4 | 115 Thousand USD | 0.0% |
2006 Q3 | - USD | 0.0% |
2005 FY | - USD | 0.0% |
2005 Q4 | - USD | 0.0% |
2005 Q3 | - USD | 0.0% |
2005 Q2 | - USD | 0.0% |
2005 Q1 | - USD | 0.0% |
2004 Q3 | - USD | 0.0% |
2004 Q1 | - USD | 0.0% |
2004 Q2 | - USD | 0.0% |
2004 Q4 | - USD | 0.0% |
2004 FY | - USD | 0.0% |
2003 Q1 | - USD | 0.0% |
2003 FY | - USD | 0.0% |
2003 Q2 | - USD | 0.0% |
2003 Q3 | - USD | 0.0% |
2003 Q4 | - USD | 0.0% |
2002 Q1 | - USD | 0.0% |
2002 Q2 | - USD | 0.0% |
2002 Q4 | - USD | 0.0% |
2002 Q3 | - USD | 0.0% |
2002 FY | - USD | 0.0% |
2001 Q3 | - USD | -100.0% |
2001 FY | - USD | -100.0% |
2001 Q2 | 1.00 USD | 0.0% |
2001 Q1 | 1.00 USD | 0.0% |
2001 Q4 | - USD | 0.0% |
2000 Q3 | 1.00 USD | 0.0% |
2000 FY | 1.00 USD | -100.0% |
2000 Q1 | 1.00 USD | -99.99% |
2000 Q4 | - USD | -100.0% |
2000 Q2 | 1.00 USD | 0.0% |
1999 Q2 | 285.17 Thousand USD | -48.34% |
1999 Q1 | 552.07 Thousand USD | -70.48% |
1999 FY | 871.15 Thousand USD | -49.65% |
1999 Q4 | 19.89 Thousand USD | 41.93% |
1999 Q3 | 14.01 Thousand USD | -95.09% |
1998 Q1 | - USD | 0.0% |
1998 Q2 | 1.48 Million USD | 0.0% |
1998 Q3 | 1.83 Million USD | 23.65% |
1998 Q4 | 1.87 Million USD | 2.19% |
1998 FY | 1.73 Million USD | 0.0% |
1997 Q2 | - USD | 0.0% |
1997 Q3 | - USD | 0.0% |
1997 Q4 | - USD | 0.0% |
1997 FY | - USD | 0.0% |
1997 Q1 | - USD | 0.0% |
1996 FY | - USD | 0.0% |
1996 Q3 | - USD | 0.0% |
1996 Q4 | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AIM ImmunoTech Inc. | 160 Thousand USD | -26470.0% |
Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 17104.8% |
Armata Pharmaceuticals, Inc. | -29.24 Million USD | 245.385% |
Actinium Pharmaceuticals, Inc. | -709 Thousand USD | 6096.051% |
Azitra, Inc. | 260.45 Thousand USD | -16222.456% |
Can-Fite BioPharma Ltd. | 743 Thousand USD | -5621.669% |
Chromocell Therapeutics Corporation | -2.57 Million USD | 1748.124% |
Calidi Biotherapeutics, Inc. | -1.25 Million USD | 3484.713% |
CEL-SCI Corporation | -3.95 Million USD | 1173.987% |
iBio, Inc. | -1.02 Million USD | 4247.512% |
Lineage Cell Therapeutics, Inc. | 8.27 Million USD | -413.802% |
MAIA Biotechnology, Inc. | - USD | -Infinity% |
Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 417.42% |
Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 35736.028% |
NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | -438.467% |
NanoViricides, Inc. | -759.01 Thousand USD | 5700.951% |
Oragenics, Inc. | -15.45 Million USD | 375.106% |
BiomX Inc. | -1.22 Million USD | 3561.889% |
BiomX Inc. | -1.22 Million USD | 3561.889% |
Palatin Technologies, Inc. | 4.39 Million USD | -867.842% |
Scorpius Holdings, Inc. | -2.21 Million USD | 2018.051% |